Navigation Links
Akela Pharma Inc. Completes Share Consolidation
Date:10/9/2007

http://www.akelapharma.com Toronto Stock Exchange Symbol: AKL

MONTREAL, Oct. 9 /PRNewswire-FirstCall/ - AKELA Pharma Inc., (TSX: AKL), a drug development company focused on developing therapies for the inhalation, pain and CNS markets, today announced that effective October 10, 2007, its issued and outstanding common shares will be consolidated on the basis of one (1) post-consolidation common share for every seven (7) pre-consolidation common shares. Fractional interests will be paid in cash in U.S. dollars for shareholders other than those in Canada who will be paid in Canadian dollars. The common shares will commence trading on the Toronto Stock Exchange on a post-consolidated basis at the opening of trading on October 10, 2007.

The share consolidation has been effected to satisfy the NASDAQ's listing criteria regarding minimum bid price. After the share consolidation, the Company will have approximately 11.75 million common shares outstanding. The stock symbol of the Company will remain AKL on the TSX.

About Akela Pharma Inc.

Akela Pharma is an integrated drug development company focused on developing therapies for the growing multi-billion dollar inhalation, pain and CNS markets. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, growth hormone deficiencies and controlled substance abuse deterrent formulations.

Akela's common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "AKL" with 82.3 million shares outstanding.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of AKELA Pharma Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncer
'/>"/>

SOURCE Akela Pharma Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. India to benefit from pharma companies move
2. South Africa Wins landmark case against pharmaceutical giants
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
5. Pharma cos must forge Strategic alliances
6. Jharkhand Pharmacies Refuse To Sell Viagra
7. Setting up a new pharmaceutical industry in India
8. Medicis Pharmaceutical company enters pediatric market
9. Supply of Radiopharmaceuticals Hampered by Attacks
10. Pharma majors gear to supply anti-anthrax drug
11. Pharmacies in for a dose of bitter medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Delhi, India (PRWEB) August 29, 2014 RBS ... named Remove Scam Book. The service is to help ... negative reviews against them on Scam Book. The service would ... results and make Scam Book complaints fully invisible on Google. ... the service. , On being asked how company can ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 A home should be ... up if unaddressed. That’s why Amica Insurance is sharing some tips ... Safety Council suggests taking the following safety measures: , Kitchen, ... – in their original containers, and keep them away from food. ... wall bracket near an exit. , Bathroom , ...
(Date:8/29/2014)... across the Arabian Peninsula and spread to Europe several ... of several hundred people since its discovery in 2012. ... how easily the pathogen spreads from human to human. ... the University of Bonn have now come to the ... transmission is low. Still, a third of infected persons ...
(Date:8/29/2014)... Glendale Botox experts at Glenoaks ... throughout the month of September. This special offer features 10 ... of Juvederm. Patients can take advantage of this special offer ... Botox experts will work with patients to determine if Botox ... is Botox? , Botox is a treatment made from ...
(Date:8/29/2014)... VHA Central Atlantic recognized Novant ... care, honoring nine facilities for meeting or exceeding national ... Novant Health, providing quality, affordable healthcare for our communities ... MD, executive vice president and chief medical officer. “These ... experience for each and every one of our patients.” ...
Breaking Medicine News(10 mins):Health News:RBS Reputation Management Announces a New Online Reputation Management Service 2Health News:Improve Home Safety with Tips from Amica Insurance 2Health News:MERS: Low transmissibility, dangerous illness 2Health News:MERS: Low transmissibility, dangerous illness 3Health News:Glenoaks Laser Center is Now Offering a Special Promotion on Botox for the Month of September 2Health News:Novant Health Recognized for Excellence in Clinical Care 2Health News:Novant Health Recognized for Excellence in Clinical Care 3
... Poster Presented at Annual Meeting of the American Academy of ... ... 11 NeoStrata today released new,clinical research that validates the benefits ... as a complement to,medical anti-aging treatments such as lasers and microdermabrasion. ...
... research from the UC Davis M.I.N.D. Institute and Center ... the blood of mothers of children with autism bind ... The study authors also found that the reaction was ... form of autism, which occurs when a period of ...
... Deerfield Spa is pleased,to announce the appointment of ... Science., "Jeanine brings outstanding credentials to Deerfield,s ... experience enable her,to fine tune our offerings so ... regimen at the spa, but also learn skills ...
... MyClyns(TM) - the Only Non-Alcohol Product that can be ... Sprayed Directly into the ... today that its revolutionary new product for use after a,potential pathogenic ... upgraded its web site, added a customer,service center and deployed regional ...
... New Patent Expands Geographic Coverage, ... Inc. (OTC Bulletin Board: CARN) today ... granted patent application No. 200600484, titled,"Delivery ... Comprising Anionic,Polysaccharides," relating to the Company,s ...
... University of Oregon scientists say they,ve discovered a ... birth defect in humans that has challenged medical ... zebrafish are present in humans and other vertebrates. ... 10-member research team isolated a disruption in early ...
Cached Medicine News:Health News:NeoStrata Research Validates Anti-Aging Benefits of At-Home AHA Peels As Complement to In-Office Non-Invasive Cosmetic Procedures 2Health News:Some cases of autism may be traced to the immune system of mothers during pregnancy 2Health News:Some cases of autism may be traced to the immune system of mothers during pregnancy 3Health News:Some cases of autism may be traced to the immune system of mothers during pregnancy 4Health News:Deerfield Spa Appoints New Fitness Director 2Health News:First Responders Acquire Revolutionary MyClyns(TM) Protective Spray 2Health News:First Responders Acquire Revolutionary MyClyns(TM) Protective Spray 3Health News:Carrington's DelSite Drug Delivery Technology Granted Patent From Eurasian Patent Office 2Health News:Carrington's DelSite Drug Delivery Technology Granted Patent From Eurasian Patent Office 3Health News:Oregon researchers discover a mechanism leading to cleft palate 2
(Date:8/28/2014)... NEW YORK , Aug. 28, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02343464/North-America-Laparoscopes-Market-Outlook-to-2020.html North ... GlobalData,s new report, "North America Laparoscopes Market ... the North America Laparoscopes market. The report provides ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire-iReach/ -- CountryFocus: ... Poland (Photo - ... CountryFocus: Healthcare, Regulatory and Reimbursement Landscape Poland " ... key trends in the healthcare market and provides ... healthcare infrastructure. Most importantly, the report provides valuable ...
(Date:8/28/2014)... Tianyin Pharmaceutical Co., Inc. (NYSE Amex: ... specializes in patented biopharmaceutical, modernized traditional Chinese medicine ... today updates the timeline for the GMP certification ... The Company is scheduled to submit the ... & Drug Administration,s (CFDA) review in the week ...
Breaking Medicine Technology:North America Laparoscopes Market Outlook to 2020 2North America Laparoscopes Market Outlook to 2020 3North America Laparoscopes Market Outlook to 2020 4North America Laparoscopes Market Outlook to 2020 5North America Laparoscopes Market Outlook to 2020 6North America Laparoscopes Market Outlook to 2020 7North America Laparoscopes Market Outlook to 2020 8North America Laparoscopes Market Outlook to 2020 9North America Laparoscopes Market Outlook to 2020 10North America Laparoscopes Market Outlook to 2020 11Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2
... Continues Biocatalysis Business Growth With a Further $4m R&D Investment -- CRAIGAVON, Northern Ireland, October 7, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we ...
... N.J., Oct. 7 Novartis Pharmaceuticals Corporation today ... Gilenya™ (fingolimod) 0.5 mg daily, a first-line oral ... was approved by the US Food and Drug ... For people with MS and healthcare professionals seeking ...
Cached Medicine Technology:Almac Continues Biocatalysis Business Growth With a Further $4m R&D Investment 2Almac Continues Biocatalysis Business Growth With a Further $4m R&D Investment 3Almac Continues Biocatalysis Business Growth With a Further $4m R&D Investment 4Almac Continues Biocatalysis Business Growth With a Further $4m R&D Investment 5Almac Continues Biocatalysis Business Growth With a Further $4m R&D Investment 6Almac Continues Biocatalysis Business Growth With a Further $4m R&D Investment 7Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 2Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 3Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 4Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 5Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 6Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya 7
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
Medicine Products: